RESUMO
INTRODUCTION: Online adaptive MR-guided radiotherapy allows for dose escalation to pancreatic cancer while sparing surrounding critical organs. We seek to evaluate the safety of delivering hypofractionated five-fraction, three-fraction and single-fraction MR-guided stereotactic ablative radiotherapy (SABR) to the pancreas. METHODS AND ANALYSIS: This is a single-centre three-arm phase 1 non-randomised safety study. Patients with localised pancreatic cancer will receive either 50 Gy in five (biological equivalent dose (BED10)=100 Gy), 39 Gy in three (BED10=90 Gy) or 25 Gy in a single fraction (BED10=87.5 Gy) MR-guided daily online adaptive radiotherapy. Each fractionation regimen will be assessed as independent cohorts to determine tolerability, assessed continuously using Bayesian conjugate posterior beta distributions. The primary endpoint of the study is to establish the safety of five-fraction, three-fraction and single-fraction MR-guided hypofractionation SABR in localised pancreatic cancer by assessing dose-limiting toxicities. Secondary endpoints include overall survival, progression-free survival, local control rates, overall control rate, resection rates, long-term toxicities and freedom from second-line chemotherapy. This study plans to also explore imaging and immune biomarkers that may be useful to predict outcome and personalise treatment. The trial will recruit up to 60 patients with a safety run-in. ETHICS AND DISSEMINATION: The trial is approved by the West Midlands-Black Country Research Ethics Committee 22/WM/0122. The results will be disseminated via conference presentations, peer-reviewed scientific journals and submission to regulatory authorities. The data collected for the study, including individual participant data, will be made available to researchers on request to the study team and with appropriate reason, via octo-enquiries@oncology.ox.ac.uk. The shared data will be deidentified participant data and will be available for 3 years following publication of the study. Data will be shared with investigator support, after approval of a proposal and with a signed data access agreement. TRIAL REGISTRATION NUMBER: ISRCTN10557832.
Assuntos
Neoplasias Pancreáticas , Hipofracionamento da Dose de Radiação , Humanos , Teorema de Bayes , Pâncreas , Neoplasias Pancreáticas/radioterapia , Hospitais Universitários , Reino Unido , Ensaios Clínicos Fase I como Assunto , Neoplasias PancreáticasRESUMO
Objective. To quantify the benefit of adaptive radiotherapy over non-adaptive radiotherapy it is useful to extract and compare dosimetric features of patient treatments in both scenarios. This requires Image-Guided Radiotherapy (IGRT) matching of baseline planning to adaptive fraction imaging, followed by extraction of relevant dose metrics. This can be impractical to retrospectively perform manually for multiple patients.Approach. Here we present an algorithm for automatic IGRT matching of baseline planning with fraction imaging and performing automated dosimetric feature extraction from adaptive and non-adaptive treatment plans, thereby allowing comparison of the two scenarios. This workflow can be done in an entirely automated way via scripting solutions given structure and dose Digital Imaging and Communications in Medicine (DICOM) files from baseline and adaptive fractions. We validate this algorithm against the results of manual IGRT matching. We also demonstrate automated dosimetric feature extraction. Lastly, we combine these two scripting solutions to extract daily adaptive and non-adaptive radiotherapy dosimetric features from an initial cohort of patients treated on an MRI guided linear accelerator (MR-LINAC).Results.Our results demonstrate that automated feature extraction and IGRT matching was successful and comparable to results performed by a manual operator. We have therefore demonstrated a method for easy analysis of patients treated on an adaptive radiotherapy platform.Significance.We believe that this scripting solution can be used for quantifying the benefits of adaptive therapy and for comparing adaptive therapy against various non-adaptive IGRT scenarios (e.g. 6 degree of freedom couch rotation).
Assuntos
Radioterapia Guiada por Imagem , Radioterapia de Intensidade Modulada , Humanos , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia Guiada por Imagem/métodos , Radioterapia de Intensidade Modulada/métodos , Estudos RetrospectivosRESUMO
BACKGROUND AND PURPOSE: Following resection of pancreatic cancer, risk of positive margins and local recurrence remain high, especially for borderline-resectable pancreatic cancer (BRPC). We aimed to establish the maximum tolerated dose of a margin-intensified five-fraction stereotactic body radiotherapy (SBRT) regimen designed to treat the region at risk. MATERIALS AND METHODS: We conducted a prospective multicentre phase-1 rolling-six dose-escalation study. BRPC patients received pre-operative SBRT, with one dose to the primary tumour and an integrated boost to the region where tumour was in contact with vasculature. Four dose-levels were proposed, with starting dose 30 Gy to primary PTV and 45 Gy to boost volume (PTV_R), in five daily fractions. Primary endpoint was maximum tolerated dose (MTD), defined as highest dose where zero of three or one of six patients experienced dose-limiting toxicity (DLT). RESULTS: Twelve patients were registered, eleven received SBRT. Radiotherapy was well tolerated with all treatment completed as scheduled. Dose was escalated one level up from starting dose without encountering any DLT (prescribed 32.5 Gy PTV, 47.5 Gy PTV_R). Nine serious adverse reactions or events occurred (seven CTCAE Grade 3, two Grade 4). Two patients went on to have surgical resection. Median overall survival for SBRT patients was 8.1 months. The study closed early when it was unable to recruit to schedule. CONCLUSION: Toxicity of SBRT was low for the two dose-levels that were tested, but MTD was not established. Few patients subsequently underwent resection of pancreatic tumour after SBRT, and it is difficult to draw conclusions regarding the safety or toxicity of these therapies in combination.
Assuntos
Neoplasias Pancreáticas , Radiocirurgia , Fracionamento da Dose de Radiação , Humanos , Dose Máxima Tolerável , Neoplasias Pancreáticas/radioterapia , Estudos Prospectivos , Radiocirurgia/efeitos adversosRESUMO
PURPOSE: Our purpose was to demonstrate the use of novel planning techniques in producing high-quality stereotactic radiosurgery (SRS) plans using a standard 5 mm multileaf collimator (MLC) and multiple isocenters delivered clinically at a local institution. METHODS AND MATERIALS: Novel planning techniques consisted of offset isocenter, variable asymmetrical jaws, and Digital Imagine and Communications in Medicine (DICOM) edits to reduce leaf tip transmission, all with the aim of maximizing dose conformity. A local institution clinical cohort was planned (1-4 targets), and plan conformity metrics common to SRS were compared against conformity metrics from selected previous publications comparing Gamma Knife to linear accelerator SRS using high-definition MLC (2.5 mm). Additionally, local institution plan conformity metrics for 2 benchmark SRS planning cases (3 and 7 targets) were compared with metrics from other centers treating SRS clinically in England. Pretreatment quality assurance results, both point dose measurement and film analysis, are presented to demonstrate plan deliverability. RESULTS: Clinical conformity metrics are shown to be comparable to previously published results using either Gamma Knife or linear accelerator with high-definition MLC. Metrics from benchmark planning cases are shown to be comparable and to have better prescription dose conformity than average nationally in England. Pretreatment quality assurance results demonstrate suitable plan deliverability. CONCLUSIONS: SRS planning using standard 5 mm MLC and multiple isocenters produces high-quality treatment plans for a limited number of targets with a high degree of dose conformity and dose fall off when employing novel planning techniques to compensate for MLC leaf size and multiple isocenters.
Assuntos
Radiocirurgia/métodos , Dosagem Radioterapêutica/normas , Planejamento da Radioterapia Assistida por Computador/métodos , Algoritmos , HumanosRESUMO
PURPOSE: Stereotactic body radiation therapy (SBRT) has emerged as a potential therapeutic option for locally recurrent rectal cancer (LRRC) but contemporaneous clinical data are limited. We aimed to evaluate the local control, toxicity, and survival outcomes in a cohort of patients previously treated with neoadjuvant pelvic radiation therapy for nonmetastatic locally recurrent rectal cancer, now treated with SBRT. METHODS AND MATERIALS: Inoperable rectal cancer patients with ≤3 sites of pelvic recurrence and >6 months since prior pelvic radiation therapy were identified from a prospective registry over 4 years. SBRT dose was 30 Gy in 5 fractions, daily or alternate days, using cumulative organ at risk dose constraints. Primary outcome was local control (LC). Secondary outcomes were progression free survival, overall survival, toxicity, and patient reported quality of life scores using the EQ visual analog scale (EQ-VAS) tool. RESULTS: Thirty patients (35 targets) were included. Median gross tumor volume size was 14.3 cm3. In addition, 27 of 30 (90%) previously received 45 to 50.4 Gy in 25 of 28 fractions, with 10% receiving an alternative prescription. All patients received the planned reirradiation SBRT dose. The median follow-up was 24.5 months (interquartile range, 17.8-28.8). The 1-year LC was 84.9% (95% confidence interval [CI], 70.6-99) and a 2-year LC was 69% (95% CI, 51.8-91.9). The median progression free survival was 12.1 months (95% CI, 8.6-17.66), and median overall survival was 28.3 months (95% CI, 17.88-39.5 months). No patient experienced >G2 acute toxicity and only 1 patient experienced late G3 toxicity. Patient-reported QoL outcomes were improved at 3 months after SBRT (Δ EQ-VAS, +10 points, Wilcoxon signed-rank, P = .009). CONCLUSIONS: Our study demonstrates that, for small volume pelvic disease relapses from rectal cancer, reirradiation with 30 Gy in 5 fractions is well tolerated and achieves an excellent balance between high local control rates with limited toxicity.
RESUMO
BACKGROUND: Delivery of SBRT to central thoracic tumours within 2â¯cm of the proximal bronchial tree (PBT), and especially ultra-central tumours which directly abut the PBT, has been controversial due to concerns about high risk of toxicity and treatment-related death when delivering high doses close to critical mediastinal structures. We present dosimetric and clinical outcomes from a group of oligometastatic patients treated with a risk-adapted SBRT approach. METHODS: Between September 2015 and October 2018, 27 patients with 28 central thoracic oligometastases (6 moderately central, 22 ultra-central) were treated with 60â¯Gy in 8 fractions under online CBCT guidance. PTV dose was compromised where necessary to meet mandatory OAR constraints. Patients were followed up for toxicity and disease status. RESULTS: Mandatory OAR constraints were met in all cases; this required PTV coverage compromise in 23 cases, with V100% reduced to <70% in 11 cases. No acute or late toxicities of Gradeâ¯≥â¯3 were reported. One and 2â¯year in-field control rates were 95.2% and 85.7% respectively, progression-free survival rates were 42.8% and 23.4% respectively, and overall survival rates were 82.7% and 69.5% respectively. No significant differences were seen in control or survival rates by extent of PTV underdosage or between moderately and ultra-central cases. CONCLUSION: It appears that compromising PTV coverage to meet OAR constraints allows safe and effective delivery of SBRT to moderately and ultra-central tumours, with low toxicity rates and high in-field control rates. This treatment can be delivered on standard linear accelerators with widely available imaging technology.
RESUMO
BACKGROUND AND PURPOSE: To determine if suppression of active bone marrow, as defined on FDG PETCT, is seen in on-treatment imaging of anal cancer patients receiving concurrent chemoradiation. METHODS AND MATERIALS: Scans from 26 patients participating in the ART trial (full title: Anal squamous cell carcinoma: Investigation of functional imaging during chemoRadioTherapy), a single center observational study with FDG PETCT prior to radiotherapy and at fraction 8-10 of concurrent chemoradiation were analysed. Active bone marrow was contoured in both the pelvis and un-irradiated thoracic spine. SUV and volume of active bone marrow after 8-10 fractions of treatment were compared to baseline. Dose metrics to pelvic active bone marrow were extracted and compared to reduction in SUV/active bone marrow volume and to blood count nadir using linear regression. RESULTS: Suppression of active bone marrow is seen in the pelvis by a reduction in mean SUV and volume of active bone marrow after 8-10 fractions of treatment. Suppression is not seen in un-irradiated thoracic spine. Dose metrics were associated with reduced SUV and reduced volume of active bone marrow. Volume of active bone marrow receiving <20â¯Gy was associated with WCC/ANC nadir. 20â¯Gy was identified as the most likely clinically meaningful dose threshold for toxicity. Volume of active bone marrow receiving <20â¯Gy correlated to WCC and ANC with an increase of 100â¯cc being associated with an increase of 0.4 and 0.3 respectively. CONCLUSION: The effect of concurrent chemoradiation in suppression of active bone marrow is seen in on-treatment FDG PETCT scans. Chemotherapy appears well tolerated after 2â¯weeks of treatment.
Assuntos
Neoplasias do Ânus , Radioterapia de Intensidade Modulada , Neoplasias do Ânus/tratamento farmacológico , Neoplasias do Ânus/terapia , Medula Óssea/diagnóstico por imagem , Quimiorradioterapia , Fluordesoxiglucose F18 , Humanos , Pelve/diagnóstico por imagemRESUMO
For semicrystalline poly(3,4-ethylene dioxythiophene) (PEDOT), oxidative chemical vapor deposition (oCVD) enables systematic control over the b-axis lattice parameter (π-π stacking distance). Decreasing the b-axis lattice parameter increases the charge transfer integral, thus enhancing intracrystallite mobility. To reduce the barrier to intercrystallite transport, oCVD conditions were tailored to produce pure face-on crystallite orientation rather than the more common edge-on orientation. The face-on oriented oCVD PEDOT with the lowest b-axis lattice parameter displayed the highest in-plane electrical conductivity (σdc = 2800 S/cm), largest optical bandgap (2.9 eV), and lowest degree of disorder as characterized by the Urbach band edge energy. With the single step oCVD process at growth conditions compatible with direct deposition onto flexible plastic substrates, the ratio σdc/σop reached 50. As compared to spun-cast PEDOT:polystyrene sulfonate, integration of oCVD PEDOT as a hole transport layer (HTL) improved both the power conversion efficiency (PCE) and shelf-life stability of inverted perovskite solar cells (PSC).
RESUMO
The photosynthetic protein, photosystem I (PSI), has been used as a photoactive species within a host of biohybrid photoelectrochemical systems. PSI multilayer films at electrode surfaces provide greatly improved solar energy conversion relative to homologous monolayer films. While the photocatalytic effect of PSI multilayers has been theorized as an electrolyte-mediated mechanism, no comprehensive, first-principles modeling study has been presented. In this work, we develop and optimize an electrochemical reaction-diffusion model to replicate the significant electrochemical, physicochemical, and transport processes that underpin photocurrent development of a PSI multilayer film. We use this model to provide strong evidence that PSI's terminal cofactors rapidly exchange electrons with diffusible mediators and stimulate photocurrent principally due to alteration of mediator concentrations at a solution-electrode interface as governed by Butler-Volmer kinetics. Our fitted model accurately replicates photocurrent trends under a variety of conditions, including variable applied bias and PSI multilayer film thickness.
Assuntos
Complexo de Proteína do Fotossistema I/química , Complexo de Proteína do Fotossistema I/efeitos da radiação , Fontes de Energia Bioelétrica , Catálise , Difusão , Eletroquímica , Eletrodos , Cinética , Modelos Químicos , Oxirredução , Processos Fotoquímicos , Spinacia oleracea/enzimologiaRESUMO
BACKGROUND AND PURPOSE: Intensity modulated radiotherapy requires all target areas to be treated by a single radiotherapy plan. In anal cancer, the pelvic nodes, inguinal nodes and primary tumour represent three different targets. We aim to calculate target-specific motion in anal cancer radiotherapy, when delivered using a single pelvic online auto-match. MATERIALS AND METHODS: Twenty consecutive patients treated using IMRT at a single institution were studied. CBCTs were retrospectively re-matched around the inguinal nodes and primary tumour. Match values were recorded relative to origin, defined as pelvic CBCT auto-match. Systematic and random errors were quantified to determine target-specific motion and suggested margins calculated using van Herk formulae. RESULTS: The suggested margins to cover the independent motion of the inguinal and anal targets for LR, CC and AP set up around the inguinal nodes were 1.5mm, 2.7mm and 2.8mm; and the primary tumour were, 4.6mm, 8.9mm and 5.2mm respectively. CONCLUSIONS: Target-specific set up will likely result in reduced treatment volumes and as such reduced toxicity. This is the first time a relationship has been described between pelvic bones, inguinal nodes and primary tumour. The PLATO study will prospectively assess the toxicity and outcomes of this target-specific margins strategy.
Assuntos
Neoplasias do Ânus/radioterapia , Carcinoma de Células Escamosas/radioterapia , Planejamento da Radioterapia Assistida por Computador/métodos , Adulto , Idoso , Neoplasias do Ânus/diagnóstico por imagem , Carcinoma de Células Escamosas/diagnóstico por imagem , Feminino , Humanos , Linfonodos/diagnóstico por imagem , Linfonodos/patologia , Masculino , Pessoa de Meia-Idade , Movimento (Física) , Pelve/diagnóstico por imagem , Pelve/patologia , Dosagem Radioterapêutica , Radioterapia de Intensidade Modulada , Estudos RetrospectivosRESUMO
BACKGROUND AND PURPOSE: Margin-directed neoadjuvant radiotherapy for borderline-resectable pancreatic cancer (BRPC) aims to facilitate clear surgical margins. A systematic method was developed for definition of a boost target volume prior to a formal phase-I study. MATERIAL AND METHODS: Reference structures were defined by two oncologists and one radiologist, target structures were submitted by eight oncologist investigators and compared using conformity indices. Resultant risk of duodenal bleed (NTCP) was modelled. RESULTS: For GTV, reference volume was 2.1cm3 and investigator mean was 6.03cm3 (95% CI 3.92-8.13cm3), for boost volume 1.1cm3 and 1.25cm3 (1.02-1.48cm3). Mean Dice conformity coefficient for GTV was 0.47 (0.38-0.56), and for boost volume was significantly higher at 0.61 (0.52-0.70, p=0.01). Discordance index (DI) for GTV was 0.65 (0.56-0.75) and for boost volume was significantly lower at 0.39 (0.28-0.49, p=0.001). NTCP using reference contours was 2.95%, with mean for investigator contour plans 3.93% (3.63-4.22%). Correlations were seen between NTCP and GTV volume (p=0.02) and NTCP and DI (correlation coefficient 0.83 (0.29-0.97), p=0.01). CONCLUSIONS: Better conformity with reference was shown for boost volume compared with GTV. Investigator GTV volumes were larger than reference, had higher DI scores and modelled toxicity risk. A consistent method of target structure definition for margin-directed pancreatic radiotherapy is demonstrated.
Assuntos
Neoplasias Pancreáticas/radioterapia , Radiocirurgia/métodos , Planejamento da Radioterapia Assistida por Computador/métodos , Humanos , Terapia Neoadjuvante/métodos , Neoplasias Pancreáticas/diagnóstico por imagem , Neoplasias Pancreáticas/cirurgia , Tomografia por Emissão de Pósitrons , Reprodutibilidade dos Testes , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND AND PURPOSE: To determine if there are differences between dose to pelvic bone marrow (PBM) using intensity modulated radiotherapy (IMRT) under UK guidance versus conformal radiotherapy (CRT) per ACT II protocol and if differences translate to rates of early haematological adverse events grade 3 or greater (HT3+). METHODS AND MATERIALS: Two groups of 20+ patients, treated under IMRT and CRT regimes respectively, were identified. All patients underwent weekly blood cell count: haemoglobin (HgB), white cell count (WCC), absolute neutrophil count (ANC) and platelets (plats). Percent volume of PBM and sub structures receiving 5-25 Gy were tested for statistical significance. Regression models were used to test for correlation to blood counts. NTCP modeling was also performed. RESULTS: PMB dose metrics showed a significant increase in the IMRT group. Regression analysis showed iliac and lumbosacral PBM dose metrics to associate with reduced nadir ANC and WCC. NTCP at HT3+ was 0.13 using IMRT relative to 0.07 using CRT (p<0.05). CONCLUSION: Whilst this is a relatively small retrospective study and lacks information on the distribution of active PBM, IMRT treatment has been shown to significantly increase PMB irradiation. PBM dose metrics have been shown to be predictive of WCC and ANC suppression. NTCP modeling predicts much high risk of HT3+. Paradoxically, actual rates of HT3+ were comparable suggesting that differences in the distributions of dose metrics maybe a significant factor and/or that there are insufficiency in the NTCP modeling.